Sinovac Biotech Ltd. (also known in China as Beijing Kexing Bioproducts) has a mission to supply vaccines to eliminate human diseases. The Chinese-based company specializes in the research, development, commercialization, and sales of human vaccines intended to treat infectious illnesses such as hepatitis A, hepatitis B, influenza and “SARS”.

Working closely with Chinese public health officials, Sinovac focuses on manufacturing and marketing human-use vaccines and related products, and is currently marketing its hepatitis A vaccine. It is also the first and only company in the world to have been granted permission to begin clinical trials for a vaccine to prevent SARS.

In May, Sinovac received a $2.86 million purchase order of hepatitis vaccine from the Chinese government to help with the earthquake victim recovery. Again in June, Sinovac received another order for vaccines from the CDC to inoculate children affected by the earthquake.

While Sinovac is showing strong sales, it has yet to show an annual net profit. However, with the influenza vaccines needed during the winter and the size of the Chinese market, Sinovac could be a major supplier to this growing market.

Let us hear your thoughts: Sinovac Biotech Ltd Message Board

Last 5 posts by QualityStocks

• Omnicity Corp. (OMCY.OB) Ensuring Effective Support for Growing Customer Base - November 25th, 2009
• Clenergen Corp.’s (CRGE.OB) Management Leads Innovative Push into Renewable Energy - November 25th, 2009
• Spending Growth Rises as Inflation Seems Manageable to Fed Despite Job Market - November 25th, 2009
• Stock Guru Featured Company: Quasar Aerospace Industries, Inc. (QASP.PK) - November 25th, 2009
• Stock Guru Featured Company: DecisionPoint Systems, Inc. (DNPI.OB) - November 25th, 2009